Close Menu

NEW YORK (360Dx) – Becton Dickinson said today that it has entered into an agreement to acquire CR Bard, a medical technology firm operating in the fields of vascular, urology, oncology, and surgical specialty products, for $317.00 per share in cash and stock, for a total price of $24 billion. The firms’ boards of directors have approved the agreement.

The combination will create “a highly differentiated medical technology company positioned to improve both the process of care and the treatment of disease for patients and healthcare providers,” the firms said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.